Gapping down
In reaction to disappointing earnings/guidance:
AMDA -27.9%,
KEYW -21.7%,
FLDM -17.2%,
PLNR -15.2%,
TWOU -14.2%,
BEBE -12.3%,
BIOS -11.6%,
POZN -8.7%,
DXPE -8.5%,
ABTL -8.4%,
UBNT -8.3%,
AVNW -7.9%,
AVID -7.4%,
MDVN -6.7%,
MNST -6%,
CNCE -5.1%,
SPPI -4.9%,
PSIX -4.8%,
NVDA -4.1%,
LIVE -3.5%,
JD -3.3%,
BBOX -3.1%,
CST -3%,
NOG -2.9%,
CA -2.7%,
JAZZ -2.5%, (Concert Pharmaceuticals and Jazz Pharmaceuticals (JAZZ) report results from their Phase 1 clinical study of JZP-386; studies do not support advancing into a later-stage clinical trial of JZP-386 at this time ),
EGY -1.9%,
TGI -1.9%,
UEPS -1.8%,
CERN -1.7%,
WAIR -1.6%,
TESO -1.6%,
CROX -1.4%,
MACK -1.3%,
FATE -1.3%,
HZNP -1.3%,
CNTY -0.8%,
HTGC -0.7%,
STON -0.7%,
NVAX -0.6%,
M&A news:
CRM -3.5% (Microsoft (MSFT) not considering bid for CRM, according to Reuters)
Other news:
LJPC -9.7% (announces it will discontinue development of its polysaccharide-based galectin-3 inhibitors, GCS-100 and LJPC-1010),
ALDX -6.2% (prices its follow-on public offering of 2,700,000 shares of its common stock at $7.50 per share),
CNCE -5.1% (Concert Pharmaceuticals and Jazz Pharmaceuticals (JAZZ) report results from their Phase 1 clinical study of JZP-386; studies do not support advancing into a later-stage clinical trial of JZP-386 at this time ),
HMTV -3.1% (prices secondary public offering of ~3.2 mln shares of Class A common stock at $12 per share),
CEMP -1.6% (filed mixed securities shelf offering),
TSLA -1.2% (small pull back from recent strength),
SMLP -0.9% (priced public offering of 6.5 mln common units at $30.75 per unit)
Analyst comments:
MHR -1.1% (downgraded to Neutral from Buy at Citigroup),
TWO -0.8% (downgraded to Mkt Perform from Outperform at Keefe